Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Neumora Therapeutics, Inc. ( (NMRA) ) has shared an update.
On February 13, 2025, Neumora Therapeutics announced leadership changes effective February 14, 2025, with Paul L. Berns transitioning to CEO and Chairman of the Board. Other key executives such as Joshua Pinto, Bill Aurora, and Michael Milligan have been assigned new roles. These changes are part of the company’s strategic efforts to enhance its position in the industry. Additionally, the Board approved an option repricing plan to incentivize key personnel, subject to stockholder approval, reflecting Neumora’s commitment to retaining talent while advancing its neuroscience initiatives.
More about Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on addressing the global brain disease crisis through innovative neuroscience drug development. The company has a pipeline of seven clinical and preclinical programs targeting neuropsychiatric disorders and neurodegenerative diseases using novel mechanisms of action and precision medicine approaches.
YTD Price Performance: -13.71%
Average Trading Volume: 3,110,019
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $274.7M
For detailed information about NMRA stock, go to TipRanks’ Stock Analysis page.
